Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards? [Yahoo! Finance]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Yahoo! Finance
medical conditions, is expected to beat estimates when it reports third-quarter 2024 results on Nov. 7, after market close. The company's commercial portfolio comprises its marketed pain-management drugs, Belbuca, Xtampza ER, Nucynta IR and Nucynta ER and Symproic, in the United States. Collegium recently diversified its commercial presence beyond pain management by foraying into the neurology market with the recent acquisition of Ironshore Therapeutics. This strategic move added Jornay PM (methylphenidate HCl), a central nervous system stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) to COLL's commercial portfolio. The Zacks Consensus Estimate for COLL's earnings per share is currently pinned at $1.63 while that for revenues is currently pegged at $161.53 million. Let's see how things might have shaped up for the upcoming quarterly release. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar Revenues generated from the third-
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? [Yahoo! Finance]Yahoo! Finance
- Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024GlobeNewswire
- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $37.00 price target on the stock.MarketBeat
COLL
Earnings
- 8/8/24 - Beat
COLL
Sec Filings
- 9/17/24 - Form 4
- 9/13/24 - Form 144
- 9/13/24 - Form 144
- COLL's page on the SEC website